Market Overview

Morgan Stanley Sees Attractive Entry Point for Abbott Laboratories

Share:
Related ABT
Abbott Seeks To Terminate Alere Acquisition: 'Not The Company We Agreed To Buy'
Wall Street's M&A Chatter From November 15
Abbott to back out of Alere deal (Seeking Alpha)

In a report published Thursday, Morgan Stanley analyst David R. Lewis reiterated an Overweight rating and $45.00 price target on Abbott Laboratories (NYSE: ABT).

In the report, Morgan Stanley noted, “The most challenging quarter of the year is behind the company and we see clarity to acceleration ahead. Consensus under-appreciates margin momentum into 2H14 and 15'. As EPS and revenue move higher into 2Q, shares will follow. Reiterate our OW thesis and $45 target.”

Abbott Laboratories closed on Wednesday at $38.38.

Latest Ratings for ABT

DateFirmActionFromTo
Sep 2016JefferiesMaintainsBuy
Aug 2016JefferiesMaintainsBuy
Jul 2016JefferiesMaintainsBuy

View More Analyst Ratings for ABT
View the Latest Analyst Ratings

Posted-In: David R. Lewis Morgan StanleyAnalyst Color Reiteration Analyst Ratings

 

Related Articles (ABT)

View Comments and Join the Discussion!